limitless biotech tirzepatide Peptide Tirzepatide Weight Loss Injections &

Taddei S, Virdis A, Ghiadoni L, Salvetti A

Regarding the risks, there is no patent risk, as the core patent is expected to expire only after 2031

75 Most heart attacks and strokes, especially ones involving plaque rupture, occur in those over 55 years of age

66 A study by He et al did not report a correlation between a single-nucleotide polymorphism associated with the gain of FGF-21 mutation and the risk of coronary artery disease and heart failure

22, 2025, the FDA approved Novo Nordisks oral Wegovy 25 mg as the first oral GLP-1 therapy for weight loss

Dysregulated Metabolic Pathways in Subjects with Obesity and Metabolic Syndrome